Trump Expands Generics Tariff, India Impact Highlighted
President Donald Trump unveiled a phased tariff plan for imported generic drugs, imposing a zero tariff for two years starting August 1, 2026, then escalating to 100% for one year and 200% thereafter to push onshoring of U.S. production and penalize companies that don’t build domestic facilities. The move expands the administration’s pharmaceutical trade policy after an earlier Section 232 action and signals potential broader application beyond generics to reshape drug supply chains.